Results 161 to 170 of about 4,608 (197)

[¹⁸F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia. [PDF]

Eur J Nucl Med Mol Imaging
Siegmund SC, Holzgreve A, Schöll M, Wenter VU, Sheikh GT, Scheifele M, Gildehaus FJ, Lindner S, Auer MK, Lottspeich C, Kroiß M, Nölting S, Völter F, Spitzweg C, Auernhammer CJ, Werner RA, Zacherl MJ.   +16 more
europepmc   +1 more source

Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions. [PDF]

Cancers (Basel)
Ghosh I, Benson O, Hernandez-Felix JH, Lin FI, Pacak K, Del Rivero J.   +5 more
europepmc   +1 more source

Anatomical-biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE. [PDF]

BMC Cancer
Bilgic S, Nazari A, Sağer MS, Sonmezoglu K.   +3 more
europepmc   +1 more source

MRI and ¹⁸F-fluorothymidine PET-MR for the early evaluation of renal and bone marrow effects in ¹⁷⁷Lu-DOTATATE therapy. [PDF]

Endocr Oncol
Dimopoulou Creusen A, Johansson E, Hagmar P, Ahlström H, Granberg D.   +4 more
europepmc   +1 more source

Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report. [PDF]

Front Endocrinol (Lausanne)
Gil Dos Santos S, Calheiros R, Oliveira J, Santos AP, Souteiro P.   +4 more
europepmc   +1 more source

Role of ¹⁸F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy. [PDF]

Front Med (Lausanne)
Liu Y, Sun Y, Zuo D, Wang H, Zheng F, Wang J, Sun X.   +6 more
europepmc   +1 more source

Expanding the therapeutic horizon of ¹⁷⁷Lu-DOTATATE: a review of current evidence. [PDF]

Nagoya J Med Sci
Minamimoto R, Kato K, Iwano S, Nishii R, Abe Y, Naganawa S.   +5 more
europepmc   +1 more source

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3. [PDF]

Pharmaceuticals (Basel)
Greifenstein L, Martin M, Stephan S, Eismant A, Kramer CS, Landvogt C, Mueller C, Rösch F, Baum RP.   +8 more
europepmc   +1 more source